Login to Your Account



NEWCO NEWS

Salt Lake City-based Alucent Medical Inc. reported it has been granted FDA approval to begin phase I trials of a combination drug/device intended to treat peripheral vascular disease (PVD).

When going after macrophages, "in my view, you play directly with the immune system," said Maxime Ranger, president and CEO of Mperia Therapeutics Inc., which is advancing macrophage-targeting immunotherapies.

Frequency Therapeutics Inc., a company working to develop a progenitor cell-activating hearing restoration therapy, has closed a $32 million series A financing led by Cobro Ventures.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: